Return to Trial Database

HCRN GU24-688

A Phase II, open-label, single-arm study of nEoadjuvant zanzalintinib (XL092) Plus nivoLumab in patients with locally advanced and/or surgically challenging clear cell Renal Cell Carcinoma with or without non-measurable metastasis (EXPLORE-RCC)

Status

Currently Enrolling

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN GU24-688 being conducted in.

UT Southwestern Harold C. Simmons Comprehensive Cancer Center